By Chris Wack

LegoChem Biosciences Inc. said Friday that it has entered into a research collaboration and license agreement with Amgen Inc.

Under the deal, Amgen was granted rights to research, develop and commercialize antibody-drug conjugates directed against up to five targets selected by Amgen based on LegoChem's proprietary ConjuAll ADC technology.

LegoChem is eligible to receive up to $1.25 billion in payments and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.

LegoChem said its clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 23, 2022 07:33 ET (12:33 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Amgen Charts.